Effects of ALPS serum and IL-17A neutralization in FICD. FICD was performed in T cells from healthy donors (A: n = 9) or patients (B: ALPS, n = 5; diamonds; DALD, n = 4; circles) in the presence of either FBS or an ALPS patient’s serum. The absolute control cell survival was similar in FBS and in the patient’s serum; *P < .05 (Wilcoxon’s signed rank test).